Overview

Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2029-07-01

Target enrollment:

Participant gender:

Summary

This study is a single-center, single-arm, prospective clinical trial evaluating the efficacy and safety of blinatumomab combined with venetoclax as maintenance therapy for high-risk Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation .

Phase:

PHASE2

Details

Lead Sponsor:

Zhejiang University

Treatments:

Maintenance
venetoclax